Naïve and Stem Memory T Cell Selection for CAR-T Toxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies face challenges such as frequent relapses, severe toxicities like cytokine release syndrome (CRS) and neurotoxicity, and limited long-term persistence, which are associated with enhanced CAR T-cell proliferation and tumor burdens, highlighting the need for improved T-cell properties and manufacturing protocols.
Innovation Solution
The method involves pre-selecting and isolating CD45RA+/CD62L+/CD95− (naïve) and CD45RA+/CD62L+/CD95+ (stem cell memory) T cells, activating them with CD3 and CD28, and expanding them with IL-7 and IL-15 to generate T cells with superior properties, including reduced toxicity and enhanced antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T-cell doses and proliferation are enhanced to improve antitumor activity, then tumor response is improved, but severity of CRS and neurotoxicity increases
Solution Approach 1:
The patent applies local quality by selecting T cells with specific differentiation statuses (naïve and stem memory) that possess locally optimized properties: high proliferative capacity and self-renewal capabilities while maintaining lower effector differentiation. This localized selection of cellular properties allows enhanced antitumor activity without the excessive activation that causes CRS and neurotoxicity.
Solution Approach 2:
The patent changes the parameter of T-cell differentiation status from more differentiated effector memory cells to less differentiated naïve and stem memory cells. This parameter change fundamentally alters the balance between proliferation capacity and activation intensity, enabling sustained antitumor responses with reduced toxicities.
2Speed
If more differentiated T cells are used to enhance immediate antitumor response, then early efficacy is improved, but long-term persistence and self-renewal capabilities are reduced
Solution Approach 1:
The patent applies preliminary action by pre-selecting and expanding naïve and stem memory T cells before infusion, thereby preparing cells with optimal self-renewal capabilities in advance. This preliminary preparation ensures that the infused cells can sustain long-term persistence and continuously generate effector cells throughout the treatment period.
Solution Approach 2:
The patent applies dynamics by creating a dynamic system where stem memory T cells serve as a renewable reservoir that continuously generates effector cells in response to tumor antigens. This dynamic structure allows the system to maintain both immediate response capacity and long-term persistence through ongoing cell generation rather than relying on a fixed pool of differentiated cells.
3Reliability
If higher peak CAR T-cell expansion is achieved to improve tumor control, then antitumor efficacy is enhanced, but incidence and severity of CRS increases
Solution Approach 1:
The patent applies preliminary action by pre-expanding naïve and stem memory T cells with high self-renewal capabilities before infusion. This preliminary expansion creates a larger reservoir of stem memory cells that can sustain prolonged proliferation in vivo without requiring excessive peak expansion, thereby achieving effective tumor control with moderated cytokine release.
Data Source
AI summary
The present invention refers to a method to produce a T cell with advantageous properties. The invention also refers to a T cell or an engineered T cell produced by the method and its use in therapy.